MIMEDX Announces Launch of EPIEFFECT™
September 26, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its...
MIMEDX to Present at Upcoming Investor Conferences
September 05, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the following investor...
MIMEDX Announces Second Quarter 2023 Operating and Financial Results
August 01, 2023 16:01 ET
|
MiMedx Group, Inc
Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive...
MIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1
July 18, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second...
MIMEDX Announces Favorable Ruling in Putative Securities Class Action Case
July 11, 2023 08:30 ET
|
MiMedx Group, Inc
MARIETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the Eleventh Circuit Court of Appeals affirmed the dismissal of...
MIMEDX Appoints Doug Rice as Chief Financial Officer
July 05, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has appointed Doug Rice as the Company’s Chief Financial...
MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business, Expected to Significantly Improve Profitability
June 20, 2023 16:01 ET
|
MiMedx Group, Inc
Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbanding Regenerative Medicine Business Unit Restructuring Expected to Generate Approximately $25 Million in Annualized...
MIMEDX Announces First Quarter 2023 Operating and Financial Results
May 02, 2023 16:01 ET
|
MiMedx Group, Inc
First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period Revenue Growth & Cost Controls Help Drive Improvements in Net Loss, EBITDA & Adjusted EBITDA1 ...
MIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2
April 18, 2023 08:00 ET
|
MiMedx Group, Inc
MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report...
MIMEDX Announces Chief Financial Officer Transition
March 23, 2023 16:01 ET
|
MiMedx Group, Inc
MARIETTA, Ga., March 23, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson,...